Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gulick, Roy M., Fatkenheuer, Gerd, Burnside, Robert, Hardy, W. David, Nelson, Mark R., Goodrich, James, Mukwaya, Geoffrey, Portsmouth, Simon, Heera, Jayvant R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: JAIDS Journal of Acquired Immune Deficiency Syndromes 2014
Gaiak:
Brief Report: Clinical Science
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3893710/
https://ncbi.nlm.nih.gov/pubmed/24419064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182a7a97a
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak